JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis

New England Journal of Medicine - Tập 366 Số 9 - Trang 787-798 - 2012
Claire Harrison1, Jean‐Jacques Kiladjian2, Haifa Kathrin Al‐Ali3, Heinz Gisslinger4, Roger J. Waltzman5, Viktoriya Stalbovskaya6, Mari McQuitty6, Deborah Hunter7, R. H. Levy7, Laurent Knoops8, Francisco Cervantes9, Alessandro M. Vannucchi10, Tiziano Barbui11, Giovanni Barosi12
1Foundation Trust, Guy's Hospital, London
2Hôpital Saint-Louis et Université Paris Diderot, Paris
3University of Leipzig, Leipzig, Germany
4Medical University of Vienna; Vienna
5Novartis Pharmaceuticals, East Hanover, NJ
6Novartis Pharma, Basel, Switzerland
7Incyte, Wilmington, DE
8Cliniques universitaires Saint-Luc, Université catholique de Louvain and Ludwig Institute for Cancer Research, Brussels
9Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona
10University of Florence, Florence
11A.O. Ospedali Riuniti di Bergamo, Bergamo
12IRCCS Policlinico San Matteo Foundation, Pavia

Tóm tắt

Từ khóa


Tài liệu tham khảo

10.1002/ajh.21183

10.1146/annurev.med.60.041707.160528

10.1182/blood-2008-07-170449

10.3816/CLM.2009.s.033

10.1016/S0140-6736(05)71142-9

10.1016/j.ccr.2005.03.023

10.1056/NEJMoa051113

10.1038/nature03546

10.1056/NEJMoa065202

10.1371/journal.pmed.0030270

10.1182/blood-2010-02-270108

10.1182/blood-2011-02-292102

10.1182/blood-2009-04-214957

10.1056/NEJMoa1002028

Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Vol. 2. 4th ed. Geneva: World Health Organization, 2008.

10.1097/00000421-198212000-00014

10.1182/blood-2006-03-009746

10.1186/1477-7525-1-79

Carter GC, 2008, Blood, 112, 828, 10.1182/blood.V112.11.828.828

10.1200/JCO.2010.32.9490

10.1177/0091270010389469

Verstovsek S, 2009, Blood, 114, 132, 10.1182/blood.V114.22.132.132

Thông tin
Thông tin xuất bản

New England Journal of Medicine

Tập 366 Số 9

787-798

Thông tin tác giả